BTIG Research Has Lowered Expectations for Evolus (NASDAQ:EOLS) Stock Price

Evolus (NASDAQ:EOLS) had its target price lowered by research analysts at BTIG Research from $18.00 to $13.00 in a research report issued on Thursday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 164.23% from the stock’s current price.

Several other research analysts have also commented on the company. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Evolus in a report on Friday, January 9th. Stifel Nicolaus cut their price target on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Mizuho cut their target price on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Evolus Price Performance

NASDAQ EOLS opened at $4.92 on Thursday. Evolus has a 1 year low of $4.74 and a 1 year high of $17.12. The stock has a market capitalization of $318.91 million, a PE ratio of -5.35 and a beta of 0.91. The company’s 50 day simple moving average is $6.45 and its two-hundred day simple moving average is $7.02.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. The business had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. On average, research analysts anticipate that Evolus will post -0.61 EPS for the current year.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. This represents a 2.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.90% of the company’s stock.

Institutional Trading of Evolus

Hedge funds have recently added to or reduced their stakes in the business. Aaron Wealth Advisors LLC bought a new position in shares of Evolus during the fourth quarter valued at about $68,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Evolus in the 4th quarter valued at about $64,000. SG Americas Securities LLC purchased a new stake in Evolus during the 4th quarter valued at about $185,000. Krensavage Asset Management LLC bought a new position in Evolus during the 3rd quarter worth approximately $614,000. Finally, Woodline Partners LP grew its position in Evolus by 92.2% during the 3rd quarter. Woodline Partners LP now owns 393,222 shares of the company’s stock worth $2,414,000 after acquiring an additional 188,660 shares during the last quarter. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.